|
Aluminium nicotinate
|
DB13576 |
|
|
Triclabendazole
|
DB12245 |
[Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food.
Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]] |
|
Allobarbital
|
DB13577 |
|
|
Inclacumab
|
DB12246 |
[Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.] |
|
AZD-4547
|
DB12247 |
[AZD4547 has been used in trials studying the treatment of Cancer, LYMPHOMA, Gastric Cancer, Adenocarcinoma, and Solid Neoplasm, among others.] |
|
Metabutethamine
|
DB13578 |
|
|
Tulobuterol
|
DB12248 |
[Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.] |
|
Mepixanox
|
DB13579 |
|
|
Emylcamate
|
DB13572 |
|
|
TAK-733
|
DB12241 |
[TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.] |
|
Acefylline
|
DB13573 |
|
|
AZD-7762
|
DB12242 |
[AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.] |
|
Edaravone
|
DB12243 |
[Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.] |
|
Heptaminol
|
DB13574 |
|
|
Bietaserpine
|
DB13575 |
|
|
CP-601927
|
DB12244 |
[CP-601,927 has been used in trials studying the basic science and treatment of Major Depressive Disorder.] |
|
Oxidized cellulose
|
DB13570 |
|
|
Pentamycin
|
DB13571 |
|
|
Polatuzumab vedotin
|
DB12240 |
[Polatuzumab vedotin is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E.[Label] This medication was granted accelerated FDA approval on 10 June 2019.[L6658]] |
|
Cefmenoxime
|
DB00267 |
[Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.] |
